ATC Code M03BX03, N04AA14
Formula C20H25NO
Molar Mass (g·mol−1) 295,42
Physical State solid
Melting Point (°C) 147–149
CAS Number 511-45-5
PUB Number 4904
Drugbank ID DB13642
Solubility schwer löslich in Chloroform, Ethylacetat und Methanol


Pridinol is a centrally acting muscle relaxant. It is used to treat muscle spasms of a central or peripheral nature. It is mainly used for lumbalgia, torticollis and general muscle pain in adults. It is used perorally in the form of tablets or by intramuscular injection.

The drug was approved in Europe in 2018.



The exact mechanism of action is not yet fully understood. However, pridinol is thought to have an atropine-like effect by blocking acetylcholine receptors in the brain, resulting in relaxation of skeletal muscle.


Complete absorption after oral administration occurs after about one hour. Pridinol is excreted partly unchanged, partly metabolized and eliminated by the kidney. The plasma half-life is between 14 and 18 hours.

Drug-Drug Interactions

When administered concomitantly with anticholinergics such as atropine, their effect may be considerably enhanced.


Adverse effects

  • Palpitations
  • Hypotension
  • Nausea
  • Gastrointestinal discomfort
  • Fatigue
  • Dizziness
  • Headache
  • Speech disorders
  • Restlessness


  • Hypersensitivity
  • Glaucoma
  • Prostatic hypertrophy
  • Urinary retention
  • Cardiac arrhythmias

Search our database for drugs, sorted from A-Z with their effects and ingredients.


All substances with their common uses, chemical components and medical products which contain them.


Causes, symptoms and treatment for the most common diseases and injuries.

The contents shown do not replace the original package insert of the medicinal product, especially with regard to dosage and effect of the individual products. We cannot assume any liability for the correctness of the data, as the data was partly converted automatically. A doctor should always be consulted for diagnoses and other health questions. Further information on this topic can be found here.